Venus Medtech (Hangzhou) Inc.

VMTHF · OTC
Analyze with AI
6/30/2025
12/31/2024
6/30/2024
12/31/2023
Revenue$187,137$240,113$230,720$235,763
% Growth-22.1%4.1%-2.1%
Cost of Goods Sold$49,149$54,127$48,960$47,807
Gross Profit$137,988$185,986$181,760$187,956
% Margin73.7%77.5%78.8%79.7%
R&D Expenses$120,928$160,351$180,834$230,200
G&A Expenses$54,785$69,451$76,575$75,893
SG&A Expenses$154,189$184,255$206,837$209,430
Sales & Mktg Exp.$100,459$114,077$130,989$142,566
Other Operating Expenses$0-$17,934$0$0
Operating Expenses$275,117$326,672$387,671$439,630
Operating Income-$137,129-$140,686-$205,911-$251,674
% Margin-73.3%-58.6%-89.2%-106.7%
Other Income/Exp. Net-$1,435-$395,958-$7,670-$113,327
Pre-Tax Income-$138,564-$536,644-$213,581-$365,001
Tax Expense$3,792-$28,096-$4,756-$2,160
Net Income-$134,772-$507,820-$206,487-$353,566
% Margin-72%-211.5%-89.5%-150%
EPS-0.31-1.16-0.47-0.81
% Growth73.3%-146.8%42%
EPS Diluted-0.31-1.16-0.47-0.81
Weighted Avg Shares Out437,898437,897437,898437,898
Weighted Avg Shares Out Dil437,897437,897437,897437,897
Supplemental Information
Interest Income$0$10,350$0$2,926
Interest Expense$7,172$16,647$0$0
Depreciation & Amortization$14,947$67,948$43,161$40,734
EBITDA-$122,182-$450,207-$162,750-$208,730
% Margin-65.3%-187.5%-70.5%-88.5%